Dr. Kshitij Verma received his Ph.D. degree in Pharmaceutical Sciences from the Texas Tech University Health Sciences Center (TX, USA) in 2018. Currently, he is working as a postdoctoral research scientist at Genentech, Inc. (CA, USA). His research interest spans areas of drug discovery, medicinal chemistry and chemical biology. Presently, he is working on the development of novel therapeutic modalities including the design, synthesis and evaluation of targeted protein degraders. Dr. Verma has authored several publications and a patent related to the discovery of potent and highly selective aldo-keto reductase 1C3 inhibitors (AKR1C3) and their effects in combating chemotherapy resistance in prostate cancer and leukemias. His research work has been recognized by several outstanding research awards from the American Association of Pharmaceutical Scientists (AAPS) and other biomedical research societies.
Dr. Kshitij Verma's research interests include Medicinal Chemistry, Organic Chemistry, Chemical Biology, Drug Discovery, Cancer Biology, Cancer Chemotherapy, Cell and Molecular Biology, Ubiquitin Proteasome System, Targeted Protein Degradation (PROTAC).